Trevi Therapeutics to Participate in Upcoming March Events
Corporate Presentation:
Presenter:
A live webcast of the
Panel Discussion: Research & Innovation, Treatments from 1:30 –
Trevi Panelist:
Register here to attend.
BIO-Europe Spring
About
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US.
Parenteral nalbuphine is not scheduled by the
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-march-events-302073494.html
SOURCE